Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization

By Karen Roman

Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics.

Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics.

At Revance we believe that science based innovative products drive confident beauty. From the first and only peptide-formulated neuromodulator, our industry-leading microneedling device, and the first hyaluronic acid fillers made for dynamic movement, our award winning products include: DAXXIFY (daxibotulinumtoxinA-Ianm) for the temporary treatment of moderate to severe frown lines in adults, the only neuromodulator manufactured in the United States, SkinPen for microneedling, and the RHA Collection by Teoxane of dermal fillers, among others. Our skincare products treat a range of skincare concerns, from acne to sun protection to anti-aging, helping people feel confident in their own skin at any age. These include: PanOxyl, Blue Lizard, and StriVectin, among others.

Exec Edge: You were named CEO of Revance on Oct. 1. What’s your vision for the company and how do you plan to bring that vision to life?

My vision is to build the most trusted, customer centric and innovative aesthetics and skincare company – one that not only leads in science and results, but also in how we serve providers, patients and customers. We have created a company that focuses on driving innovation beyond convention, with unmatched expertise across regenerative, injectables and skincare. We are focused on more than just scale – we are shaping the next era of aesthetics, grounded in science, authenticity and partnership with our customers.

Exec Edge: What are the benefits of having aesthetics, therapeutics and consumer skincare divisions all operating under the Revance name?

As a unified company, we combine cutting-edge innovation in aesthetics and therapeutics with our deep roots in science-powered brands for skin health and rejuvenation. With our industry leading, comprehensive range of aesthetic solutions, we offer one of the most expansive portfolios of innovative aesthetic and consumer skin health brands.

Exec Edge: What do you view as the biggest areas of opportunity for Revance?

Our commercial acceleration represents an immediate area of opportunity. We have a differentiated product portfolio, particularly with DAXXIFY, the first and only peptide-formulated neuromodulator in the market, but we’re still in the early stages of realizing its full market potential. By expanding our sales force, expanding provider and patient education, and deepening our market penetration, we know we can not only accelerate revenue growth, but start to shift an industry to think beyond the status quo.

Exec Edge: What are your expansion plans?

International markets remain a huge opportunity for Revance. We currently have several products available internationally, including StriVectin, SkinPen, MicroPen EVO, PanOxyl, Blue Lizard and we look forward to making international markets a bigger part of our revenue portfolio. Within the U.S., we’re heavily focused on increasing awareness of DAXXIFY, which just recently passed 1M vials sold in the U.S., and we see a long runway for growth and expansion of DAXXIFY for aesthetics and in therapeutics.

Exec Edge: How does Revance differentiate itself from your competitors?

Revance is vertically integrated across aesthetics and skincare, with U.S.-based manufacturing of skincare and DAXXIFY, the only neuromodulator manufactured in the U.S., providing greater supply chain control, faster market responsiveness, and science-based, differentiated products delivering exceptional results. With an integrated portfolio spanning in-office procedures and at-home skincare, in-house quality and testing labs, high customer centricity, and leadership in key growth segments including regenerative, injectables, acne, and sun protection, Revance has top-performing brands and a strong runway for accelerated growth as awareness of its differentiated products continues to expand.

Exec Edge: What trends across aesthetics, skincare and therapeutics does Revance hope to capitalize on?

We are capitalizing on key trends across aesthetics and skincare, including the intersection of wellness and beauty, where demand for moisturizers with SPF 30 is growing and being addressed through new StriVectin launches. In aesthetics, regenerative procedures continue to expand, with SkinPen holding the #1 position and with new innovation coming. The company is also meeting demand for clean and natural, eco-friendly sun protection through Blue Lizard mineral sunscreen. DAXXIFY, the first and only peptide-formulated neuromodulator, offers long-lasting results that give patients a radiant look. Additionally, the Teoxane RHA Collection, featuring RHA Dynamic Volume for balanced restoration and natural-looking outcomes in patients with midface volume deficiencies, like those on GLP-1 therapies.

More broadly, these trends reflect growing provider and patient interest in solutions that enhance appearance while supporting long-term skin health. Revance’s integrated portfolio across aesthetics, skincare, and therapeutics positions the company to offer care throughout an individual’s lifetime, while advances in technology and AI are expected to further enable personalized treatment approaches and accelerate innovation over time.

Exec Edge: Where do you expect Revance will be in 5 years?

Looking ahead five years, I envision Revance as continuing to redefine excellence in aesthetics, skincare, and therapeutics through science powered innovation, with an unwavering commitment to providers, patients and consumers. I see Revance with a meaningful presence across key international markets, not only driving revenue growth, but gleaning diverse market insights to fuel innovation and inform our R&D efforts.

READ MORE